RPG Investment Advisory LLC boosted its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 131.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 70,335 shares of the biopharmaceutical company’s stock after buying an additional 40,002 shares during the period. Gilead Sciences makes up 1.6% of RPG Investment Advisory LLC’s holdings, making the stock its 16th largest position. RPG Investment Advisory LLC’s holdings in Gilead Sciences were worth $5,862,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of the stock. Joel Isaacson & Co. LLC raised its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Loomis Sayles & Co. L P raised its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the period. Jolley Asset Management LLC raised its stake in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares during the period. North Star Investment Management Corp. raised its stake in Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares during the period. Finally, Stanley Laman Group Ltd. purchased a new stake in Gilead Sciences during the second quarter valued at $205,000. 77.94% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.92% during midday trading on Monday, reaching $80.62. The company’s stock had a trading volume of 4,456,068 shares. The stock’s 50-day moving average is $79.46 and its 200 day moving average is $85.89. The stock has a market capitalization of $106.39 billion, a P/E ratio of 7.08 and a beta of 1.06. Gilead Sciences Inc. has a 12 month low of $76.67 and a 12 month high of $111.11.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter in the previous year, the company posted $3.15 earnings per share. Gilead Sciences’s revenue for the quarter was down 5.7% compared to the same quarter last year. On average, analysts expect that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.31%. Gilead Sciences’s dividend payout ratio is 16.56%.
Several research firms have weighed in on GILD. Piper Jaffray Cos. set a $108.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, August 21st. Jefferies Group reaffirmed a “hold” rating and set a $96.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 29th. Morgan Stanley reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Sunday, May 29th. RBC Capital Markets reaffirmed an “outperform” rating and set a $105.00 price objective (down previously from $120.00) on shares of Gilead Sciences in a research note on Tuesday, July 26th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $120.00 price objective (down previously from $123.00) on shares of Gilead Sciences in a research note on Thursday, June 9th. Nine analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $105.26.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total value of $9,444,960.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman John C. Martin sold 100,000 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $84.73, for a total value of $8,473,000.00. Following the completion of the transaction, the chairman now owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.